HPV and cervical cancer: screening or vaccination?
Open Access
- 8 January 2008
- journal article
- review article
- Published by Springer Nature in British Journal of Cancer
- Vol. 98 (1) , 15-21
- https://doi.org/10.1038/sj.bjc.6604146
Abstract
Following the demonstration of the superior validity of human papillomavirus (HPV) tests in screening for cervical cancer and the arrival of highly efficacious HPV 16 and 18 vaccines, cervical cancer prevention enters a time of sustainable introduction in developing countries. Multidisciplinary efforts and novel protocols are being developed, and challenging situations are being faced to make cervical cancer, still the number two cancer in women worldwide, an eradicable condition.Keywords
This publication has 31 references indexed in Scilit:
- Challenges of implementing human papillomavirus (HPV) vaccination policyBMJ, 2007
- Model for Assessing Human Papillomavirus Vaccination StrategiesEmerging Infectious Diseases, 2007
- The Absolute Risk of Cervical Abnormalities in High-risk Human Papillomavirus–Positive, Cytologically Normal Women Over a 10-Year PeriodCancer Research, 2006
- Chapter 15: HPV vaccine use in the developing worldVaccine, 2006
- Chapter 9: Clinical applications of HPV testing: A summary of meta-analysesVaccine, 2006
- Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccinationVaccine, 2006
- Human Papillomavirus Testing and Liquid-Based Cytology: Results at Recruitment From the New Technologies for Cervical Cancer Randomized Controlled TrialJNCI Journal of the National Cancer Institute, 2006
- Overview of the European and North American studies on HPV testing in primary cervical cancer screeningInternational Journal of Cancer, 2006
- The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical PracticeJNCI Journal of the National Cancer Institute, 2005
- Cost-effectiveness of Human Papillomavirus DNA Testing in the United Kingdom, The Netherlands, France, and ItalyJNCI Journal of the National Cancer Institute, 2005